These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

488 related items for PubMed ID: 27803306

  • 1. Both prolonged remission and Lupus Low Disease Activity State are associated with reduced damage accrual in systemic lupus erythematosus.
    Tsang-A-Sjoe MW, Bultink IE, Heslinga M, Voskuyl AE.
    Rheumatology (Oxford); 2017 Jan; 56(1):121-128. PubMed ID: 27803306
    [Abstract] [Full Text] [Related]

  • 2. Glucocorticoids and irreversible damage in patients with systemic lupus erythematosus.
    Ruiz-Arruza I, Ugarte A, Cabezas-Rodriguez I, Medina JA, Moran MA, Ruiz-Irastorza G.
    Rheumatology (Oxford); 2014 Aug; 53(8):1470-6. PubMed ID: 24681836
    [Abstract] [Full Text] [Related]

  • 3. Comparison of Remission and Lupus Low Disease Activity State in Damage Prevention in a United States Systemic Lupus Erythematosus Cohort.
    Petri M, Magder LS.
    Arthritis Rheumatol; 2018 Nov; 70(11):1790-1795. PubMed ID: 29806142
    [Abstract] [Full Text] [Related]

  • 4. Treatment Target in Newly Diagnosed Systemic Lupus Erythematosus: The Association of Lupus Low Disease Activity State and Remission With Lower Accrual of Early Damage.
    Floris A, Piga M, Perra D, Chessa E, Congia M, Mathieu A, Cauli A.
    Arthritis Care Res (Hoboken); 2020 Dec; 72(12):1794-1799. PubMed ID: 31600023
    [Abstract] [Full Text] [Related]

  • 5. Lupus low disease activity state is associated with a decrease in damage progression in Caucasian patients with SLE, but overlaps with remission.
    Zen M, Iaccarino L, Gatto M, Saccon F, Larosa M, Ghirardello A, Punzi L, Doria A.
    Ann Rheum Dis; 2018 Jan; 77(1):104-110. PubMed ID: 28970217
    [Abstract] [Full Text] [Related]

  • 6. LLDAS (lupus low disease activity state) and/or remission are associated with less damage accrual in patients with systemic lupus erythematosus from a primarily Mestizo population: data from the Almenara Lupus Cohort.
    Ugarte-Gil MF, Gamboa-Cardenas RV, Reátegui-Sokolova C, Pimentel-Quiroz VR, Medina M, Elera-Fitzcarrald C, Zevallos F, Pastor-Asurza CA, Lofland J, Zazzetti F, Karyekar CS, Alarcón GS, Perich-Campos RA.
    Lupus Sci Med; 2022 Feb; 9(1):. PubMed ID: 35193948
    [Abstract] [Full Text] [Related]

  • 7. Flare rates and factors determining flare occurrence in patients with systemic lupus erythematosus who achieved low disease activity or remission: results from a prospective cohort study.
    Hao Y, Ji L, Gao D, Fan Y, Geng Y, Zhang X, Li G, Zhang Z.
    Lupus Sci Med; 2022 Mar; 9(1):. PubMed ID: 35241499
    [Abstract] [Full Text] [Related]

  • 8. Failure to achieve lupus low disease activity state (LLDAS) six months after diagnosis is associated with early damage accrual in Caucasian patients with systemic lupus erythematosus.
    Piga M, Floris A, Cappellazzo G, Chessa E, Congia M, Mathieu A, Cauli A.
    Arthritis Res Ther; 2017 Nov 10; 19(1):247. PubMed ID: 29126432
    [Abstract] [Full Text] [Related]

  • 9. Frequencies and predictors of the Lupus Low Disease Activity State and remission in treatment-naïve patients with systemic lupus erythematosus.
    Gao D, Hao Y, Mu L, Xie W, Fan Y, Ji L, Zhang Z.
    Rheumatology (Oxford); 2020 Nov 01; 59(11):3400-3407. PubMed ID: 32337549
    [Abstract] [Full Text] [Related]

  • 10. Longitudinal associations of active renal disease with irreversible organ damage accrual in systemic lupus erythematosus.
    Kandane-Rathnayake R, Kent JR, Louthrenoo W, Luo SF, Wu YJ, Lateef A, Golder V, Sockalingam S, Navarra SA, Zamora L, Hamijoyo L, Katsumata Y, Harigai M, Chan M, O'Neill S, Goldblatt F, Lau CS, Hoi A, Nikpour M, Morand E.
    Lupus; 2019 Dec 01; 28(14):1669-1677. PubMed ID: 31718467
    [Abstract] [Full Text] [Related]

  • 11. Glucocorticoid withdrawal in systemic lupus erythematosus: are remission and low disease activity reliable starting points for stopping treatment? A real-life experience.
    Tani C, Elefante E, Signorini V, Zucchi D, Lorenzoni V, Carli L, Stagnaro C, Ferro F, Mosca M.
    RMD Open; 2019 Dec 01; 5(2):e000916. PubMed ID: 31275608
    [Abstract] [Full Text] [Related]

  • 12. Determinants and protective associations of the lupus low disease activity state in a prospective Chinese cohort.
    Hao Y, Oon S, Ji L, Gao D, Fan Y, Geng Y, Zhang X, Li G, Morand EF, Nikpour M, Zhang Z.
    Clin Rheumatol; 2022 Feb 01; 41(2):357-366. PubMed ID: 34595670
    [Abstract] [Full Text] [Related]

  • 13. Remission and low disease activity (LDA) prevent damage accrual in patients with systemic lupus erythematosus: results from the Systemic Lupus International Collaborating Clinics (SLICC) inception cohort.
    Ugarte-Gil MF, Hanly J, Urowitz M, Gordon C, Bae SC, Romero-Diaz J, Sanchez-Guerrero J, Bernatsky S, Clarke AE, Wallace DJ, Isenberg DA, Rahman A, Merrill JT, Fortin PR, Gladman DD, Bruce IN, Petri M, Ginzler EM, Dooley MA, Ramsey-Goldman R, Manzi S, Jönsen A, van Vollenhoven RF, Aranow C, Mackay M, Ruiz-Irastorza G, Lim S, Inanc M, Kalunian K, Jacobsen S, Peschken C, Kamen DL, Askanase A, Pons-Estel BA, Alarcón GS.
    Ann Rheum Dis; 2022 Nov 01; 81(11):1541-1548. PubMed ID: 35944946
    [Abstract] [Full Text] [Related]

  • 14. Remission and low disease activity in Polish patients with systemic lupus erythematosus - real-life, five-year follow-up outcomes.
    Pawlak-Buś K, Schmidt W, Leszczyński P.
    Eur Rev Med Pharmacol Sci; 2023 Feb 01; 27(3):949-959. PubMed ID: 36808341
    [Abstract] [Full Text] [Related]

  • 15. Frequency and predictors of the lupus low disease activity state in a multi-national and multi-ethnic cohort.
    Golder V, Kandane-Rathnayake R, Hoi AY, Huq M, Louthrenoo W, An Y, Li ZG, Luo SF, Sockalingam S, Lau CS, Lee AL, Mok MY, Lateef A, Franklyn K, Morton S, Navarra ST, Zamora L, Wu YJ, Hamijoyo L, Chan M, O'Neill S, Goldblatt F, Morand EF, Nikpour M, Asia-Pacific Lupus Collaboration.
    Arthritis Res Ther; 2016 Nov 09; 18(1):260. PubMed ID: 27829463
    [Abstract] [Full Text] [Related]

  • 16. The chronic damage in systemic lupus erythematosus is driven by flares, glucocorticoids and antiphospholipid antibodies: results from a monocentric cohort.
    Conti F, Ceccarelli F, Perricone C, Leccese I, Massaro L, Pacucci VA, Truglia S, Miranda F, Spinelli FR, Alessandri C, Valesini G.
    Lupus; 2016 Jun 09; 25(7):719-26. PubMed ID: 26821965
    [Abstract] [Full Text] [Related]

  • 17. Definition and initial validation of a Lupus Low Disease Activity State (LLDAS).
    Franklyn K, Lau CS, Navarra SV, Louthrenoo W, Lateef A, Hamijoyo L, Wahono CS, Chen SL, Jin O, Morton S, Hoi A, Huq M, Nikpour M, Morand EF, Asia-Pacific Lupus Collaboration.
    Ann Rheum Dis; 2016 Sep 09; 75(9):1615-21. PubMed ID: 26458737
    [Abstract] [Full Text] [Related]

  • 18. Predictors of low disease activity and clinical remission following belimumab treatment in systemic lupus erythematosus.
    Parodis I, Johansson P, Gomez A, Soukka S, Emamikia S, Chatzidionysiou K.
    Rheumatology (Oxford); 2019 Dec 01; 58(12):2170-2176. PubMed ID: 31157891
    [Abstract] [Full Text] [Related]

  • 19. Long-Term Clinical Outcomes in a Cohort of Adults With Childhood-Onset Systemic Lupus Erythematosus.
    Groot N, Shaikhani D, Teng YKO, de Leeuw K, Bijl M, Dolhain RJEM, Zirkzee E, Fritsch-Stork R, Bultink IEM, Kamphuis S.
    Arthritis Rheumatol; 2019 Feb 01; 71(2):290-301. PubMed ID: 30152151
    [Abstract] [Full Text] [Related]

  • 20. Low disease activity-irrespective of serologic status at baseline-associated with reduction of corticosteroid dose and number of flares in patients with systemic lupus erythematosus treated with belimumab: A real-life observational study.
    Fanouriakis A, Adamichou C, Koutsoviti S, Panopoulos S, Staveri C, Klagou A, Tsalapaki C, Pantazi L, Konsta S, Mavragani CP, Dimopoulou D, Ntali S, Katsikas G, Boki KA, Vassilopoulos D, Konstantopoulou P, Liossis SN, Elezoglou A, Tektonidou M, Sidiropoulos P, Erden A, Sfikakis PP, Bertsias G, Boumpas DT.
    Semin Arthritis Rheum; 2018 Dec 01; 48(3):467-474. PubMed ID: 29555348
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 25.